Summary
AbbVie Inc. (ABBV) filed an 8-K on February 2, 2022, primarily to furnish its press release announcing fourth quarter and full-year 2021 financial results. While the 8-K itself does not contain detailed financial figures, it directs investors to the press release (Exhibit 99.1) for this crucial information. Investors should review this press release to understand AbbVie's performance, including revenue, earnings per share, and any forward-looking guidance provided for 2022. The key takeaway for investors from this filing is the availability of AbbVie's most recent financial performance data. The 8-K serves as the official notification that this information has been disseminated. Therefore, investors should access the furnished press release to gain insights into the company's operational and financial condition as reported for the period ending December 31, 2021, and any outlook the company has shared.
Key Highlights
- 1AbbVie filed an 8-K on February 2, 2022, to announce its Q4 and full-year 2021 financial results.
- 2The 8-K formally incorporates by reference a press release containing the detailed financial results.
- 3Investors must refer to the furnished press release (Exhibit 99.1) for specific financial performance data.
- 4The filing indicates the company is reporting on its financial condition and operational results.
- 5This report provides the official channel for disseminating AbbVie's latest financial outcomes.